Abstracts | 51 gyrus (DG) fail to mature (Yamasaki et al., Mol. Brain, 2008; Hagihara et al. Cell Reports, in press), in several genetic mouse models that display behavioral abnormalities related to psychiatric disorders. Additionally, chronic administration of fluoxetine, selective serotonin reuptake inhibitor, which is used to treat depression, induces "dematuration" of DG neurons: mature DG neurons go back to pseudo-immature state (Kobayashi et al., PNAS, 2010). However, whether there is any relationship between stress and maturation of DG remains to be understood. Here, we examined the effects of repeated stress on maturation of DG neurons in C57BL/6J mice and BALB/c mice, which are known to be more susceptible to stress and more anxious than C57BL/6J mice. Animals were subjected to repeated restraint stress for 3 or 6 weeks. The gene and protein expressions of maturation markers of DG neurons were analyzed by real-time PCR and immunohistochemical methods, and anxiety-like and depression-like behaviors were assessed. Repeated stress downregulated maturation markers (desmoplakin, tryptophan 2, 3-dioxygenase, and calbindin) and upregulated an immature marker (BDNF) in BALB/c mice. No changes of such markers were detected in C57BL/6J mice. Repeated stress also led to decreased protein expressions of calbindin and glucocorticoid receptor in the DG of BALB/c mice. Additionally, repeated stress induced hyperlocomotor activity and increased depression-like behaviors in BALB/c mice. These results suggest that repeated restraint stress alters maturation state of the DG neurons in BALB/c mice, which may underlie some of the stress-induced behavioral changes.
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Interleukin-18-deficient mice develop dysfunction of hippocampus resulting in depression-like behavior Kyosuke Yamanishi 1, 6 , Nobutaka Doe 4, 5 Department of Anatomy and Cell Biology, 3 Laboratory of Tumor Immunology and Cell Therapy, and 4 Laboratory of Neurogenesis and CNS Repair, Hyogo College of Medicine, Mukogawa, Nishinomiya, 5 Department of Psychology, Hyogo University of Health Sciences, Minatojima, Kobe, 6 Hirakata General Hospital for Developmental Disorders, Hirakata, Japan Abstract Objectives: Major depressive disorder (MDD) is a common disorder that has been implicated in marked disabilities in global functioning, anorexia, and severe medical comorbidity, and also known as being closely related to inflammation. We found that interleukin-18-deficient (Il18 −/− ) mice exhibit dysfunction of the hippocampus resulting in depression-like behavior. To verify the mechanism of MDD, the relation between interleukin-18 (IL-18), which is one of the inflammatory cytokines and the hippocampus were examined in this study.
Methods: Il18
−/− male mice were generated on the C57Bl/6 mice background as previously described (Takeda K, et al. Immunity. 1998) . Littermate C57Bl/6 Il18 +/+ male mice were used as controls. For behavioral analysis of depression and hippocampal functions, we used -open space swimming test, tail suspension test, and water maze learning were performed. In addition, immunostaining and electron-microscope were performed for histopathological analyses.
Results: Our behavioral analysis indicated that Il18
−/− mice might show the disability of learning and memory comparing to Il18+/+ mice. Moreover, in the hippocampus of Il18 −/− mice, the marker of neurogenesis in immunostaining and morphological changes could be observed in the dentate gyrus of the hippocampus. Conclusions: These findings suggested that deficiency of IL-18 can lead to dysfunction of the hippocampus resulting in behavioral changes, such as those associated with MDD.
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Comparative efficacy of various augmentation strategies for treatment-resistant depression: a meta-analysis of randomized controlled trials Abstract Objectives: Since the introduction of newer antidepressants, there have been great advances in treatments for major depression. However, many patients with major depression have inadequate responses to standard therapy. To date, many studies that investigated the efficacy of various treatment strategies for treatment resistant depression have been conducted. We investigate whether there are differences in the effect size of various augmentation strategies according to the degree of treatment resistance. Methods: A comprehensive literature search was performed using multiple databases. We performed this meta-analysis using Cochrane review methods. The primary outcome variable of this meta-analysis was response rate in patients with treatment resistant depression who were treated with alternative augmentation strategies in addition to standard antidepressant therapy. Results: A comprehensive literature search identified 20 randomized controlled trials. The nineteen studies, which included 3,628 participants, were pooled using a random-effects model to compare the effect sizes among various treatment strategies. We conducted subgroup analyses according to the degree of treatment resistance defined as the number of failed trials during current index episode (TRD 1 and TRD 2 or higher). The seven studies, which included 638 participants, were pooled to compare the effect sizes among various strategies in the TRD 1 trials. Various augmentation strategies for treatment resistant depression included lithium augmentation, antidepressant combination, augmentation with thyroid hormone, pindolol augmentation, augmentation with atypical antipsychotics, augmentation with stimulants. The 8 studies, which included 696 participants, were pooled to compare the effect sizes in the TRD 2 or higher trials. Overall, there was no significant difference in the effect sizes among various strategies in treatment resistant depression in terms of response rates (Response, risk ratio (RR)= 1.45 (95% confidence interval (CI) 1.25 to 1.67); Test for subgroup differences, Chi 2 =2.57, df=5, P=0.77, I 2 =0%). For TRD 1 trials, there was no significant difference in the effect sizes among various strategies (Response, risk ratio (RR)= 1.43 (95% confidence interval (CI) 1.10 to 1.85); Test for subgroup differences, Chi 2 =3.69, df=3, P=0.30, I 2 =18.7%). For TRD 2 or higher trials, there seemed to be a significant difference in the effect sizes among strategies. The efficacy for atypical antipsychotics has well-founded evidence (RR=1.52 (95% CI= 1.33 to 1.74), n=2052) The evidence regarding the efficacy of other strategies were insufficient. Among them, lithium augmentation showed relatively small effect size (RR=0.63 (95% CI= 0.12 to 3.32)), while augmentation with thyroid hormone (RR= 3.14 (95% CI= 1.05 to 9.38)) or pindolol (RR=10.80 (95% CI = 0.75 to 155.93)) showed large effect sizes. Conclusion: Overall, there seemed to be no significant differences in effect sizes among different augmentation strategies for Table 1 . Overall relative risk ratios of response rates for various augmentation strategies in treatment-resistant depression treatment resistant depression. However, according to the degree of treatment resistance, despite insufficient evidence, there seemed to be a meaningful difference in effect sizes among various strategies.
Further studies to investigate the comparative efficacy of various alternative strategies for treatment resistant depression are needed to draw a more definitive conclusion regarding their efficacy. Table 2 . Relative risk ratios of response rates for various augmentation strategies in TRD 1 trialsTRD 1, treatment resistant depression, defined by history of a treatment failure to standard antidepressant therapy within the current depressive episode.
